HOME
| Pipeline | Development Phase | ||||
|---|---|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 | ||
| Neurodegenerative disease | EFL-101 |
|
|||
| Incurable disease | EFL-301 |
|
|||
| Musculoskeletal disease | EFL-501 |
|
|||
| EFL-601 |
|
||||
| Sensory organ disease | EFL-201 |
|
|||
| EFL-901 |
|
||||
| EFL-1101 |
|
||||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||
| Development Phase | |||
|---|---|---|---|
| Hit to Lead | Candidate | Preclinical | Phase 1 |
|
|
|||